Michael A Liss1, Yidong Chen2, Ronald Rodriguez2, Deepak Pruthi2, Teresa Johnson-Pais2, Hanzhang Wang2, Ahmed Mansour2, Dharam Kaushik2. 1. Department of Urology, University of Texas Health San Antonio, San Antonio, TX; Department of Cell and Molecular Biology, University of Texas Health San Antonio, San Antonio, TX; Department of Epidemiology and Biostatistics, University of Texas Health San Antonio, San Antonio, TX; GreeheyChildren's Cancer Research Institute, University of Texas Health San Antonio, SanAntonio, TX. Electronic address: liss@uthscsa.edu. 2. Department of Urology, University of Texas Health San Antonio, San Antonio, TX; Department of Cell and Molecular Biology, University of Texas Health San Antonio, San Antonio, TX; Department of Epidemiology and Biostatistics, University of Texas Health San Antonio, San Antonio, TX; GreeheyChildren's Cancer Research Institute, University of Texas Health San Antonio, SanAntonio, TX.
Abstract
OBJECTIVE: To perform immune-cell enumeration and programmed death-ligand 1 (PD-L1) expression in clear cell renal cell carcinoma (cc-RCC) with tumor thrombus (TT) to guide therapeutic decisions. METHODS: After obtaining IRB approval and surgical consent, 6 patients underwent radical nephrectomy with venous tumor thrombectomy. We utilized RNA Sequencing to obtain RNAseq expression profiles. Computational calculation and enumeration of immune cells were performed using CIBERSORT, xCell, and ingenuity pathway analysis software. Statistical assessment was conducted using a t test, chi-square, ANOVA and Spearman rank correlations using SPSS v21. RESULTS: We observed a higher proportion of M1 macrophages in the primary tumor and tumor thrombus, while we noted no difference in M2 macrophages despite M2 representing a high number in thrombus samples. (ANOVA, P = .032, and P = .89, respectively). Validation with xCell and ingenuity pathway analysis analysis showed a high involvement of macrophages. We observed a higher number of M1 macrophages (CIBERSORT mean 0.11 vs 0.03, P < 0.01) and (nonactivated) resting Natural Killer (NK) cells (0.077 vs 0.017, P = .02) associated PD-L1 high expression of the primary tumor. PDL1 expression was variable without differences in tumor stage, level, or immune cell detection. We observed an inverse correlation of mean platelet volume with PD-L1 expression within the primary tumor (Spearman, -0.89, P = 02) and the TT (Spearman, -0.77, P = 0.07). CONCLUSION: Renal tumor thrombus has higher levels of M1 macrophages that could be utilized as additional targets for future drug development. The PD-L1 expression on clear cell RCC biopsy may not represent its corresponding TT. Future studies are needed to confirm mean platelet volume as a potential blood-based biomarker for PD-L1 expression in RCC.
OBJECTIVE: To perform immune-cell enumeration and programmed death-ligand 1 (PD-L1) expression in clear cell renal cell carcinoma (cc-RCC) with tumor thrombus (TT) to guide therapeutic decisions. METHODS: After obtaining IRB approval and surgical consent, 6 patients underwent radical nephrectomy with venous tumor thrombectomy. We utilized RNA Sequencing to obtain RNAseq expression profiles. Computational calculation and enumeration of immune cells were performed using CIBERSORT, xCell, and ingenuity pathway analysis software. Statistical assessment was conducted using a t test, chi-square, ANOVA and Spearman rank correlations using SPSS v21. RESULTS: We observed a higher proportion of M1 macrophages in the primary tumor and tumor thrombus, while we noted no difference in M2 macrophages despite M2 representing a high number in thrombus samples. (ANOVA, P = .032, and P = .89, respectively). Validation with xCell and ingenuity pathway analysis analysis showed a high involvement of macrophages. We observed a higher number of M1 macrophages (CIBERSORT mean 0.11 vs 0.03, P < 0.01) and (nonactivated) resting Natural Killer (NK) cells (0.077 vs 0.017, P = .02) associated PD-L1 high expression of the primary tumor. PDL1 expression was variable without differences in tumor stage, level, or immune cell detection. We observed an inverse correlation of mean platelet volume with PD-L1 expression within the primary tumor (Spearman, -0.89, P = 02) and the TT (Spearman, -0.77, P = 0.07). CONCLUSION:Renal tumor thrombus has higher levels of M1 macrophages that could be utilized as additional targets for future drug development. The PD-L1 expression on clear cell RCC biopsy may not represent its corresponding TT. Future studies are needed to confirm mean platelet volume as a potential blood-based biomarker for PD-L1 expression in RCC.
Authors: Andres J Schrader; Sandra Steffens; Thomas J Schnoeller; Mark Schrader; Markus A Kuczyk Journal: Int J Urol Date: 2012-05-28 Impact factor: 3.369
Authors: Ahmed Q Haddad; Christopher G Wood; E Jason Abel; Laura-Maria Krabbe; Oussama M Darwish; R Houston Thompson; Jennifer E Heckman; Megan M Merril; Bishoy A Gayed; Arthur I Sagalowsky; Stephen A Boorjian; Vitaly Margulis; Bradley C Leibovich Journal: J Urol Date: 2014-04-02 Impact factor: 7.450
Authors: Aaron M Newman; Chih Long Liu; Michael R Green; Andrew J Gentles; Weiguo Feng; Yue Xu; Chuong D Hoang; Maximilian Diehn; Ash A Alizadeh Journal: Nat Methods Date: 2015-03-30 Impact factor: 28.547
Authors: Łukasz Zapała; Michał Kunc; Sumit Sharma; Rafał Pęksa; Marta Popęda; Wojciech Biernat; Piotr Radziszewski Journal: J Cancer Res Clin Oncol Date: 2022-08-30 Impact factor: 4.322
Authors: Michael A Liss; Yidong Chen; Ronald Rodriguez; Deepak Pruthi; Teresa Johnson-Pais; Hanzhang Wang; Ahmed Mansour; James R White; Dharam Kaushik Journal: Adv Urol Date: 2020-02-18